HE4 And CA-125 Combined Test For Ovarian Cancer Screening
The HE4 and CA-125 combined test is a dual biomarker blood screening that measures two specific proteins associated with ovarian tissue changes. This combined approach may provide enhanced information compared to using either marker individually, particularly when evaluating pelvic masses or monitoring women at higher risk for gynaecological conditions.
Important clinical note: HE4 and CA-125 combined testing is a risk assessment and clinical evaluation tool. It is not currently recommended by NICE or the NHS as a population-based ovarian cancer screening programme. Its primary use is in the evaluation of symptomatic women, those with identified pelvic masses, or as part of monitoring under specialist guidance. Any results should be interpreted by a qualified healthcare professional.
For context on how individual HE4 and CA-125 markers support risk assessment, our earlier guide on understanding HE4 and CA-125 for risk assessment covers each biomarker in depth.
Practical Insight: Combining these biomarkers can help healthcare professionals make more informed decisions about further investigations.
Understanding The Individual Biomarkers
CA-125 (Cancer Antigen 125)
CA-125 is a protein that can become elevated in various conditions affecting the ovaries, fallopian tubes, and other pelvic structures. While widely recognised in gynaecological assessment, CA-125 levels can also rise due to benign conditions including endometriosis, fibroids, and inflammatory processes.
HE4 (Human Epididymis Protein 4)
HE4 is a newer biomarker that may show fewer fluctuations related to benign gynaecological conditions compared to CA-125. This protein is naturally present in low levels but can increase when certain ovarian tissue changes occur.
The ROMA Algorithm: Enhanced Assessment
| Component | Purpose | Calculation Method |
|---|---|---|
| HE4 Level | Primary biomarker measurement | Blood concentration (pmol/L) |
| CA-125 Level | Secondary biomarker measurement | Blood concentration (U/mL) |
| Menopausal Status | Risk stratification factor | Pre/post-menopausal classification |
| ROMA Score | Combined risk assessment | Mathematical algorithm result |
The Risk of Ovarian Malignancy Algorithm (ROMA) combines both biomarker levels with menopausal status to generate a percentage score that may help assess the likelihood of finding malignant versus benign conditions.
Who Should Consider This Combined Testing?
Women With Pelvic Masses
When imaging studies identify pelvic masses, the HE4 and CA-125 combined test can provide additional information to help guide appropriate specialist referral pathways. This is particularly relevant for women where surgical planning requires enhanced risk assessment.
High-Risk Family History
Women with strong family histories of ovarian or breast cancer may benefit from periodic monitoring using these biomarkers as part of a comprehensive screening approach, though genetic counselling should be considered first. Our post on advanced female health panels versus standard tests helps contextualise where combined biomarker testing sits within broader women’s health screening.
Persistent Symptoms
The combination test might be appropriate for women experiencing persistent pelvic symptoms, bloating, or abdominal discomfort that hasn’t responded to initial management approaches.
Practical Insight: The combined test is most valuable when used as part of a broader clinical assessment rather than as an isolated screening tool.
Understanding Your Results
Normal Range Considerations
Both biomarkers have established reference ranges, though these can vary by laboratory, menopausal status, and individual factors. CA-125 is commonly referenced at below 35 U/mL as a general guide, while HE4 reference ranges vary by age and menopausal status. These thresholds should not be self-interpreted — the ROMA Score is expressed as a percentage risk assessment and requires clinical context to be meaningful.
Elevated Results: What They May Indicate
Elevated biomarkers don’t automatically indicate serious conditions. Many benign factors can influence levels including menstrual cycle timing, pregnancy, endometriosis, ovarian cysts, inflammatory conditions, and recent surgery.
The Importance Of Clinical Context
Results are always interpreted alongside symptoms, physical examination findings, and imaging studies. No single biomarker test can provide a definitive diagnosis independently.
Testing Frequency And Monitoring
Initial Assessment
For women undergoing evaluation of pelvic symptoms or masses, this may be a one-time assessment to inform immediate clinical decisions.
Ongoing Monitoring
Some women with higher risk profiles might benefit from periodic testing, typically at 6–12 month intervals, though this should be determined based on individual risk factors and specialist recommendations.
Post-Treatment Monitoring
Women who have previously received treatment for ovarian conditions may use these biomarkers for ongoing monitoring, with frequency determined by their specialist care team.
London Healthcare Context
In London’s diverse healthcare landscape, many private clinics offer comprehensive women’s health screening that includes advanced biomarker testing. Private testing can be particularly valuable when symptoms require prompt assessment, family history suggests higher risk, or routine monitoring is recommended by specialists. Any concerning results should be promptly shared with NHS services or appropriate specialists for ongoing care.
For women considering a comprehensive approach, our post on platinum full body MOT for women outlines how HE4/CA-125 testing sits alongside other women’s health markers in an integrated screening package.
Limitations And Considerations
False Positives And Negatives
No biomarker test is completely accurate. Both false positive results (elevated levels without serious conditions) and false negative results (normal levels despite underlying conditions) can occur.
Complementary Testing
The HE4 and CA-125 combination works best when combined with detailed symptom assessment, physical examination, appropriate imaging studies, and specialist evaluation when indicated.
Practical Insight: Think of biomarker testing as one piece of a larger puzzle rather than a standalone answer.
Integration With Comprehensive Health Screening
Many women choose to include HE4 and CA-125 testing as part of broader health screening packages that may also encompass cardiovascular risk assessment, diabetes screening, and other cancer markers. For context on how ovarian health markers compare with other cancer-related biomarkers, our post on AFP liver cancer marker testing illustrates how different tumour markers are applied in different clinical contexts.
This comprehensive approach can provide valuable baseline information and identify multiple risk factors simultaneously, allowing for more informed health management decisions.
For women with BRCA gene variants or significant family history of ovarian cancer, understanding the appropriate monitoring cadence is particularly important — our post on frequency guidelines for ovarian health monitoring with BRCA mutations provides detailed guidance on recommended screening intervals.
Frequently Asked Questions
What does the HE4 and CA-125 combined test involve?
A simple blood test measuring two specific proteins. No special preparation is usually required, though timing during the menstrual cycle may be considered.
How accurate is the HE4 and CA-125 combined test for ovarian cancer screening?
The combination provides more comprehensive information than either marker alone, but no biomarker test is completely accurate. Results must always be interpreted within clinical context.
Can I have this test during my menstrual cycle?
Yes, though some healthcare providers prefer testing during specific cycle phases. Your testing provider can advise on optimal timing.
What happens if my HE4 and CA-125 levels are elevated?
Elevated levels don’t automatically indicate serious conditions. Further assessment, often including imaging and specialist consultation, would typically be recommended.
Does the HE4 and CA-125 test replace cervical screening?
No, this biomarker test assesses different aspects of gynaecological health. Regular cervical screening remains important and should continue as recommended.
What’s the difference between CA-125 alone and the combined test?
The combination may provide more comprehensive information, particularly for distinguishing between benign and potentially concerning conditions affecting the ovaries.
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. HE4, CA-125, and ROMA results must be interpreted by a qualified healthcare professional in the context of your individual symptoms, history, and clinical findings. If you have concerns about your gynaecological health, please consult a doctor promptly.
Next review: May 2027.